Fibroblast-Derived Exosomes for Angiogenesis Without Cell Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for critical limb ischemia and other conditions requiring angiogenesis stimulation face challenges in effectively leveraging the therapeutic potential of exosomes without the drawbacks of cell delivery and storage, and existing angiogenic factor administrations have shown mixed clinical results.
Innovation Solution
The use of fibroblast-derived exosomes, cultured under hypoxic conditions and purified through anion exchange chromatography, to stimulate angiogenesis by delivering therapeutic signals directly to endothelial cells and inducing pro-angiogenic cytokine production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cell therapy is used to deliver therapeutic signals, then therapeutic efficacy is improved, but storage and delivery complexity increases
Solution Approach 1:
The patent extracts the therapeutic signaling function from whole cells by isolating exosomes that contain therapeutic miRNAs and other bioactive molecules. This extraction allows the therapeutic signals to be delivered without the complexity of storing and delivering entire cells, resolving the contradiction between maintaining therapeutic efficacy and reducing delivery system complexity
Solution Approach 2:
The patent creates a simplified copy of cell therapy by using exosomes that replicate the therapeutic signaling functions of whole cells. These exosome-based copies deliver the same therapeutic miRNAs and signals without requiring the complex infrastructure needed for cell storage, handling, and delivery
2Ease of operation
If exosomes are used for therapeutic delivery, then cell therapy drawbacks are avoided, but purification complexity increases
Solution Approach 1:
The patent employs a segmented purification approach using anion exchange chromatography that separates exosomes based on their surface charge properties. This segmentation strategy isolates exosomes from other cellular components through a systematic multi-step process, managing the purification complexity while achieving high purity therapeutic product
Solution Approach 2:
The patent uses anion exchange resin as an intermediary medium to facilitate exosome purification. The resin acts as a mediator that selectively binds exosomes based on their anionic surface properties, enabling separation from other cellular components without requiring complex equipment or procedures
3Reliability
If hypoxic culture conditions are used for fibroblasts, then angiogenic potential is improved, but culture complexity increases
Solution Approach 1:
The patent changes the oxygen concentration parameter in the culture environment from standard atmospheric levels (21% O2) to hypoxic conditions (lower O2 levels). This parameter change mimics physiological ischemic conditions, enhancing the fibroblasts' angiogenic potential and the therapeutic content of secreted exosomes while using a relatively simple culture modification
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Fibroblast-derived exosomes enhance angiogenesis by stimulating VEGF production and endothelial cell proliferation, demonstrating potential for limb salvage and improved treatment outcomes in animal models.
Implementation Method 1
Exosomes are nanoparticles (40-100nm) in size that possess highly defined homogeneous characteristics
Implementation Method 2
the fibroblasts are cultured under hypoxia
Implementation Method 3
purified through anion exchange chromatography
Data Source
Figure 1
Figure 2
AI summary
Disclosed are methods, means, and compositions of matter useful for the stimulation of angiogenesis directly by administration of membrane vesicles, such as fibroblast-derived exosomes, and/or through induction of angiogenic cytokines from blood cells contacted with fibroblast-derived exosomes. The invention provides means of treating conditions in which angiogenesis is beneficial through local or systemic administration of exosomes, including those derived from fibroblasts, wherein the fibroblasts are cultured under basal conditions or conditions of hypoxia. In other embodiments exosomes derived from fibroblasts are utilized to augment endogenous regenerative processes, such as hematopoiesis, angiogenesis and neurogenesis, as well as augment regenerative processes stimulated by administration of exogenous therapeutics such as cells, growth factors, or genes.